Dosage form: tablet, delayed release
Drug class:5-aminosalicylates
Medically reviewed by Drugs.com. Last updated on May 1, 2022.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
- Medication Guide
1. INDICATIONS AND USAGE
Mesalamine delayed-release tablets are indicated for the:
- •
- induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis.
Pediatric use information is approved for Takeda Pharmaceuticals U.S.A., Inc.'s LIALDA (mesalamine) delayed-release tablets. However, due to Takeda Pharmaceuticals U.S.A., Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.
2. DOSAGE AND ADMINISTRATION
Administration Instructions
- •
- Evaluate renal function prior to initiation of mesalamine and periodically while on therapy.
- •
- Swallow mesalamine delayed-release tablets whole; do not split or crush.
- •
